HOME >> MEDICINE >> NEWS
FDA approves new indication for Topamax as initial monotherapy for adults and children with epilepsy

TITUSVILLE, NJ, June 30, 2005 -- The U.S. Food and Drug Administration (FDA) yesterday approved a new use for TOPAMAX (topiramate) Tablets and TOPAMAX (topiramate capsules) Sprinkle Capsules as initial monotherapy in patients 10 years of age and older with partial-onset or primary generalized tonic-clonic seizures.

Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than two seizures in the three months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.

"Anti-epilepsy medications, or neuromodulators, are selected based on seizure type; however, the specific seizure type may not always be obvious at the time of diagnosis," said Tracy Glauser, M.D., director of the Comprehensive Epilepsy Center at the Cincinnati Childrens Hospital. "A treatment like TOPAMAX, which provides coverage for both partial-onset and primarily generalized tonic-clonic seizures, offers doctors an option in situations where differentiating between these seizure types is difficult."

Epilepsy is characterized by seizures, which are abnormal electrical discharges in the brain that temporarily disrupt normal brain function. Seizures are classified as "generalized," originating in both sides of the brain simultaneously, or "partial-onset," starting in one area of the brain.

In a double-blind clinical trial, 470 patients with partial-onset or primary generalized tonic-clonic seizures were randomized to treatment with 50 mg or 400 mg/day of TOPAMAX. The primary efficacy assessment was a group comparison of time to first seizure during the double-blind phase of the study. Comparison of the Kaplan-Meier survival curves of time to first seizure favored the 400 mg/day group over the 50mg/day group. The recommended dose for monotherapy in patients 10 years of age and older is 400 mg/da
'"/>

Contact: Debbie Harvey
dharvey@golinharris.com
312-729-4374
Golin/Harris International
30-Jun-2005


Page: 1 2 3

Related medicine news :

1. DFG approves 11 new Collaborative Research Centers
2. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
3. FDA approves Dey, L.P.s Perforomist inhalation solution for maintenance treatment of COPD
4. VCR -- FDA approves home discharge for US patients
5. FDA approves prescription Zaditor for over-the-counter relief from itchy eyes
6. FDA approves Vectibix to treat patients with metastatic colorectal cancer
7. 5,000 rare diseases need drugs, but Europe only approves a handful each year
8. FDA approves room temperature storage of ZLB Behrings Helixate FS
9. FDA approves first blood test to predict risk for stroke
10. FDA approves Boostrix a new US vaccine for adolescents against pertussis
11. Majority of herb users dont follow evidence-based indications, researchers find

Post Your Comments:
(Date:3/6/2015)... Lewisville, Texas (PRWEB) March 06, 2015 ... at 7am today. The new facility is located at 13351 ... , “Our experienced clinical team is ready 24-7 to provide ... said Dr. Grossman, Facility Medical Director of First Choice Emergency ... a ribbon cutting with the South Metro Denver Chamber of ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Utilizing the ... and rapidly reach their ideal weight has enabled Diet ... to their already impressive collection of fat loss ... existing clients special promotions and savings to help people ... immediately. This promotion is especially appealing to new ...
(Date:3/6/2015)... Aliso Viejo, California (PRWEB) March 06, 2015 ... entitled Pro3rd Hue from Pixel Film Studios. , “Pro3rd Hue ... style.” Said Christina Austin, CEO of Pixel Film Studios. “Blurring ... definite game changer.” , Pro3rd Hue is a set of ... Final Cut Pro X. With Pro3rd Hue, FCPX users can ...
(Date:3/6/2015)... Medical Products, Inc., a Mississippi Corporation, announced ... Healthcare to become an authorized distributor for GE Healthcare ... has 31 years in distribution within the U.S. and ... agreement, MPI will have the opportunity to extend services ... , MPI has always strived to provide our customers ...
(Date:3/5/2015)... global digital PCR (dPCR) and qPCR market is expected to reach ... 2019. , The global digital PCR (dPCR) and qPCR market is ... 2019. Although the mature markets such as the U.S., Germany, France ... qPCR market the Asia-Pacific region is expected to grow at the ... the digital PCR (dPCR) and qPCR market is driven by factors ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 2Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 3Health News:Diet Doc Announces Never Before Offered Discounts, Promotions and Savings for New and Existing Clients 4Health News:A New Plugin Entitled Pro3rd Hue was Released Today from Pixel Film Studios Exclusively for FCPX 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4
(Date:3/5/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology, and medical device industries, with ... its financial results for the fourth quarter and full ... , Net Revenues Increased 21.3% Year Over Year to ... 17.7% Year Over Year to $140.5 Million , ...
(Date:3/5/2015)... and TÜBINGEN, Germany , March ... Gates Foundation and CureVac today announced that the ... million (€46 million) in CureVac, a leading clinical-stage ... part of the agreement, the foundation will also ... prophylactic vaccines based on CureVac,s proprietary messenger RNA ...
(Date:3/5/2015)... LITTLE FALLS, N.J. , March 5, 2015 ... the results for its second quarter ended January 31, 2015 ... a conference call to discuss the results at 11:00 AM ... dial (877) 407-8033 approximately 5 to 10 minutes before the ... a digital replay of the call will be available from ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 2The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 3The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
Cached News: